《大行報告》花旗下調聯易融-W(09959.HK)目標價至9.4元 評級「買入」
花旗發表報告,指聯易融-W(09959.HK)2022年上半年收入大致符合預期,在供應鏈受干擾下,預計2022年第四季將會復甦,將其目標價由11元下調至至9.4元,維持評級「買入」。
該行認為,以按季計算,預計聯易融2022年第三季可能會繼續受到疫情影響,但第四季有望錄得更強勁的增長勢頭,尤其是對於e鏈雲(e-chain)來說,隨著疫情緩和,金融機構被壓抑的需求得以釋放。
花旗指,截至2022年上半年,聯易融現金餘額按年增長4.6%至60億元人民幣,使公司處於有利地位考慮併購。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.